DRUG News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$506.0M

Volume

50.72K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Bright Minds Biosciences to Present at Jefferies Global Healthcare ConferenceBright Minds Biosciences announced it will present at the Jefferies Global Healthcare Conference on June 3, 2026. The company also granted 109,000 stock options to directors, officers, and consultants at an exercise price of US$83.40 per share, vesting over four years.GlobeNewswire Inc. · May 26, 2026

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug PipelineB Group, Inc. initiated a new position in Bright Minds Biosciences by purchasing 67,500 shares worth approximately $5.43 million in Q1 2026. The investment signals confidence in the company's epilepsy drug pipeline, particularly BMB-101. Bright Minds is a pre-clinical biotech firm with a well-funded balance sheet (C$309.7 million in cash) and no commercial revenue, representing a high-risk, high-reward opportunity for long-term investors.The Motley Fool · May 21, 2026

Bright Minds Biosciences Announces Closing of US$175 Million Public OfferingBright Minds Biosciences (NASDAQ: DRUG) successfully closed a public offering of 1.945 million common shares at US$90 per share, raising US$175.05 million in gross proceeds. The company plans to use the net proceeds to fund clinical trials for drug candidates targeting absence seizures, DEE, Prader-Willi Syndrome, and BMB-105, along with R&D and general corporate purposes.Benzinga · Jan 9, 2026

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common StockBright Minds Biosciences priced an upsized public offering of 1,945,000 common shares at $90 per share for gross proceeds of $175.05 million. The company plans to use net proceeds to fund clinical trials for drug candidates targeting absence seizures, DEE, and Prader-Willi Syndrome, as well as phase 1 trials for BMB-105. The offering is expected to close on January 9, 2026.GlobeNewswire Inc. · Jan 8, 2026

Why Bright Minds Biosciences Stock Topped the Market on MondayBright Minds Biosciences strengthened its scientific advisory board with four experts in Prader-Willi Syndrome, launching a new investigational drug program targeting the rare genetic disorder. The company will evaluate existing and new treatment candidates, with initial Phase 1 studies focusing on safety and tolerability.The Motley Fool · Nov 17, 2025

Bright Minds Biosciences to Present at Upcoming ConferencesBright Minds Biosciences will present at the Guggenheim Healthcare Innovation Conference and Jefferies Global Healthcare Conference in November 2025, and has granted stock options to directors, officers, and consultants.GlobeNewswire Inc. · Oct 30, 2025

Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder UpdateFirefly Neuroscience, a Nasdaq-listed AI company, announced its Q3 2024 financial results and provided updates on its partnerships with pharmaceutical companies like Bright Minds Bioscience, Novartis, and Takeda to advance its Brain Network Analytics (BNA) technology for neurological and mental disorder treatments.GlobeNewswire Inc. · Nov 14, 2024

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private PlacementBright Minds Biosciences Inc. has closed a $35 million private placement, with participation from several healthcare investors. The company plans to use the proceeds for research and development related to its drug development programs.GlobeNewswire Inc. · Nov 4, 2024

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25thBright Minds Biosciences announced the initiation of a Phase 2 clinical trial of BMB-101, a novel 5-HT2C agonist, for the treatment of drug-resistant epilepsies. The company will host a KOL event to discuss the trial and the unmet needs in epilepsy care.GlobeNewswire Inc. · Sep 19, 2024

Why Cutera Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Wednesday's SessionGainers Tango Therapeutics, Inc. (NASDAQ: TNGX) climbed 85.2% to $7.09 after gaining 11% on Tuesday. Tango Therapeutics recently posted a narrower quarterly loss. Decibel Therapeutics, Inc. (NASDAQ: DBTX) gained 76% to $4.9150 after Regeneron announced it will acquire the company. Benitec Biopharma Inc. (NASDAQ: BNTC) jumped 75.8% to $3.3937. Benitec Biopharma reported pricing of $30 million underwritten public offering. Renovaro Biosciences Inc. (NASDAQ: RENB) shares gained 68.2% to $1.43 after the company and AI-focused GEDi Cube announced a binding, exclusive letter of intent to merge. T Stamp Inc. (NASDAQ: IDAI) climbed 48.8% to $2.3518. EBET, Inc. (NASDAQ: EBET) surged 40.5% to $0.0405 on abnormally-high volume. The stock was set to be suspended at the opening of business today unless the company requested an appeal of Nasdaq's Listing Qualifications Department's determination. Millennium Group International Holdings Limited (NASDAQ: MGIH) gained 40% to $2.7003 on strong volume. Science 37 Holdings, Inc. (NASDAQ: SNCE) jumped 39.3% to $0.3765 following better-than-expected quarterly results. BioNexus Gene Lab Corp. (NASDAQ: BGLC) gained 36.5% to $1.5699. Kubient, Inc. (NASDAQ: KBNT) rose 33.7% to $0.63. Oportun Financial Corporation (NASDAQ: OPRT) gained 31.3% to $6.90 following strong quarterly results. Poseida Therapeutics, Inc. (NASDAQ: PSTX) climbed 31.3% to $2.60 following quarterly results. Mirati Therapeutics, Inc. (NASDAQ: MRTX) surged 30.1% to $36.17 after the company reported second-quarter financial results. Also, B. Riley Securities upgraded the stock from Neutral to Buy and announced a $45 price target. Allbirds, Inc. (NASDAQ: BIRD) gained 29% to $1.65 after the company reported better-than-expected second-quarter financial results. Array Technologies, Inc. (NASDAQ: ARRY) climbed 27.8% to $22.85 following a second-quarter earnings beat. Computer Task Group, Incorporated (NASDAQ: CTG) gained 27.8% to $10.23 after the company announced it will be acquired by Cegeka for $10.50 per share. LivePerson, Inc. (NASDAQ: LPSN) rose 27.5% to $5.09 r after the company announced a second-quarter earnings beat. The company named John Collins as the Interim CEO. PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) gained 22.3% to $8.31 after the company reported better-than-expected second-quarter EPS results. Celsius Holdings, Inc. (NASDAQ: CELH) jumped 21.8% to $174.73 after the company reported better-than-expected second-quarter financial results. United Insurance Holdings Corp. (NASDAQ: UIHC) gained 21.3% to $6.83. DMC Global Inc. (NASDAQ: BOOM) climbed 19.8% to $21.03 following quarterly results. Dutch Bros Inc. (NYSE: BROS) surged 19.8% to $33.55 after the company reported better-than-expected quarterly EPS results and issued FY23 guidance. Azenta, Inc. (NASDAQ: AZTA) gained 19.6% to $57.45 fter the company reported better-than-expected third-quarter financial results and issued fourth-quarter EPS guidance above estimates. Additionally, Needham raised its price target from $55 to $65 on the stock. ThredUp Inc. (NASDAQ: TDUP) climbed 19.5% to $3.85 after the company reported better-than-expected second-quarter financial results and issued revenue guidance. Also, Goldman Sachs raised its price target from $3 to $4 on the stock. Planet Green Holdings Corp. (NASDAQ: PLAG) rose 17.5% to $0.5670. Anavex Life Sciences Corp. (NASDAQ: AVXL) climbed 16.2% to $ 9.33. Rapid7, ...Benzinga · Aug 9, 2023

DRUGBright Minds Biosciences Inc. Common Stock

DRUG

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any DRUG yet.

Related Tickers

Earnings

Mkt Cap

$508.1M

Volume

50.72K